Related Experiment Video
Updated: Jul 10, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Darunavir
Wissam I El-Atrouni1, Zelalem Temesgen
1Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA.
Abstract:
Darunavir is a nonpeptidic protease inhibitor recently approved for the treatment of antiretroviral therapy-experienced patients. It has potent in vitro activity against viral isolates that are resistant to currently licensed protease inhibitors. In randomized clinical trials with optimized background regimens, it has shown virologic and immunologic responses superior to comparator-based regimens.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Retroviruses
Inhibitors Of Virion Release
Subviral Agents
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
